Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 380843-75-4 | Product Number: B4824
Bosutinib
×
![]()
×
Purity: >95.0%(T)(HPLC)
Synonyms:
- SKI-606
- 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
- 4-(2,4-Dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 250MG |
€195.00
|
Contact Us | 30 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | B4824 |
| Purity / Analysis Method | >95.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__6H__2__9Cl__2N__5O__3 = 530.45 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Hygroscopic |
| CAS RN | 380843-75-4 |
| Reaxys Registry Number | 9100307 |
| MDL Number | MFCD07367846 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Purity(Volumetric Analysis) | min. 95.0 % |
| Water | max. 5.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 120 °C |
| Solubility in water | Insoluble |
| Degree of solubility in water | 7 mg/l 25 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H319 : Causes serious eye irritation. H317 : May cause an allergic skin reaction. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P261 : Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. P273 : Avoid release to the environment. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P333 + P313 : If skin irritation or rash occurs: Get medical advice/ attention. |
Related Laws:
| RTECS# | VB0990000 |
Transport Information:
| HS Number | 2933998090 |
Application
Bosutinib: A Potent ATP-Competitive Tyrosine Kinase Inhibitor
Bosutinib (SKI-606) is a potent ATP-competitive tyrosine kinase inhibitor. Bosutinib has been reported to inhibit the Bcr-Abl kinase, which promotes chronic myeloid leukemia (CML). Inhibition of Bcr-Abl tyrosine kinase activity or signaling proteins activated by Bcr-Abl in CML cells blocks proliferation and causes apoptotic cell death. Bosutinib is also inhibits the phosphorylation of cellular signaling proteins, including Src-family kinases (Src, Lyn, and Hck) and STAT5. (The product is for research purpose only.)
References
- SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice
- In vitro and in vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells
- Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
- Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.